Literature DB >> 15027904

Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.

Hidenobu Kamohara1, Wataru Matsuyama, Osamu Shimozato, Koichiro Abe, Carole Galligan, Shin-Ichi Hashimoto, Kouji Matsushima, Teizo Yoshimura.   

Abstract

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, which is capable of inducing apoptosis in many cell types, including tumour and virus-infected cells, but rarely in normal cells. Expression of TRAIL mRNA and TRAIL receptors has previously been detected in neutrophils; however, the expression of TRAIL protein and the regulation of TRAIL and TRAIL receptor expression in these cells remain unknown. Here we report, for the first time, that neutrophils constitutively express TRAIL protein on their cell surface and that the TRAIL protein is shed during culture. TNF-alpha is a down-regulator of TRAIL expression, whereas IFN-gamma up-regulates the expression of TRAIL. Neutrophils did not express a detectable level of TRAIL-R1 or -R4, but constitutively expressed a low, but substantial, level of TRAIL-R2 and a high level of TRAIL-R3. Although the level of TRAIL-R2 was not significantly altered during culture under different experimental conditions, approximately 30% of TNF-alpha-treated cells rapidly lost their high-level TRAIL-R3 expression, whereas the majority of IFN-gamma-treated cells retained a high level of TRAIL-R3 expression. Anti-TRAIL neutralizing antibody significantly inhibited neutrophil apoptosis during cultures in medium alone, or in the presence of TNF-alpha or IFN-gamma. Thus, our study identified human neutrophils as a cellular source of TRAIL and suggests that neutrophil-derived TRAIL may play a role in immune surveillance. Our results also suggest a role for the TRAIL/TRAIL receptor system in neutrophil apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027904      PMCID: PMC1782413          DOI: 10.1111/j.0019-2805.2003.01794.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice.

Authors:  Salah-Eddine Lamhamedi-Cherradi; Shi-Jun Zheng; Kimberly A Maguschak; Jacques Peschon; Youhai H Chen
Journal:  Nat Immunol       Date:  2003-02-10       Impact factor: 25.606

2.  Acceleration of human neutrophil apoptosis by TRAIL.

Authors:  Stephen A Renshaw; Jasvir S Parmar; Vanessa Singleton; Sarah J Rowe; David H Dockrell; Steven K Dower; Colin D Bingle; Edwin R Chilvers; Moira K B Whyte
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

3.  Identification and characterization of a new member of the TNF family that induces apoptosis.

Authors:  S R Wiley; K Schooley; P J Smolak; W S Din; C P Huang; J K Nicholl; G R Sutherland; T D Smith; C Rauch; C A Smith
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

4.  Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha.

Authors:  D B Dubravec; D R Spriggs; J A Mannick; M L Rodrick
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Prognosis in breast cancer utilizing histologic characteristics of the primary tumor.

Authors:  M M Black; T H Barclay; B F Hankey
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

6.  cDNA cloning of guinea pig monocyte chemoattractant protein-1 and expression of the recombinant protein.

Authors:  T Yoshimura
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

7.  Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors: binding and signaling of MCP3 through shared as well as unique receptors on monocytes and neutrophils.

Authors:  L L Xu; D W McVicar; A Ben-Baruch; D B Kuhns; J Johnston; J J Oppenheim; J M Wang
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

8.  Mononuclear stromal reactions in mammary carcinoma, with special reference to medullary carcinomas with a lymphoid infiltrate. Analysis of 108 cases.

Authors:  R Bässler; A M Dittmann; M Dittrich
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

9.  Inhibition of tumor growth by elimination of granulocytes.

Authors:  L A Pekarek; B A Starr; A Y Toledano; H Schreiber
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  23 in total

1.  Early transcriptional response of human neutrophils to Anaplasma phagocytophilum infection.

Authors:  Bindu Sukumaran; Jason A Carlyon; Ji-Lian Cai; Nancy Berliner; Erol Fikrig
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  Mechanisms regulating neutrophil survival and cell death.

Authors:  María Laura Gabelloni; Analía Silvina Trevani; Juan Sabatté; Jorge Geffner
Journal:  Semin Immunopathol       Date:  2013-02-01       Impact factor: 9.623

3.  Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.

Authors:  Amelia A Romoser; Patricia L Chen; J Michael Berg; Christopher Seabury; Ivan Ivanov; Michael F Criscitiello; Christie M Sayes
Journal:  Mol Immunol       Date:  2011-04-09       Impact factor: 4.407

Review 4.  Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role?

Authors:  Roberta Della Bona; Maria Teresa Cardillo; Milena Leo; Gina Biasillo; Massimo Gustapane; Francesco Trotta; Luigi M Biasucci
Journal:  Inflamm Res       Date:  2013-04-03       Impact factor: 4.575

5.  ADAM17 activity and other mechanisms of soluble L-selectin production during death receptor-induced leukocyte apoptosis.

Authors:  Yue Wang; Adam C Zhang; Zhenya Ni; Amy Herrera; Bruce Walcheck
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

6.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 7.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

Review 8.  Role of neutrophils in BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; Michael A O'Donnell; Thomas S Griffith
Journal:  Urol Oncol       Date:  2008 Jul-Aug       Impact factor: 3.498

Review 9.  Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.

Authors:  Mark P Simons; William M Nauseef; Thomas S Griffith
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 10.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.